IAVI Begins First Doses In "Open Label" Investigational Clinical Trial -- Ebola Sudan Strain Vaccine, Deployed -- In Kampala, Uganda...

Well. . . it turns out that at least the first dosings in Kampala will not be the one under development at/by Soligenix.

The non-profit international alliance for vaccines, IAVI, will use a self-developed Sudan variant vaccine candidate with these first 44 contacts in Kampala. Here's that story:

. . .The first participants have been vaccinated with an investigational Ebola Sudan vaccine candidate provided by IAVI, a nonprofit scientific research organization, as part of a World Health Organization (WHO)-led ring vaccination trial taking place at Makerere University Lung Institute in Kampala. WHO prioritized evaluation of IAVI’s candidate vaccine, which was already prepositioned in Uganda, as part of a global collaborative effort supporting the country’s Ebola outbreak response.

This is Uganda’s sixth outbreak of Ebola Sudan, which causes severe hemorrhagic fever disease with a case fatality rate of up to 50%. No licensed vaccines or therapeutics are available for Ebola Sudan, a Category A priority pathogen. Existing Ebola Zaire vaccines are not cross-protective for Ebola Sudan. . . .

Onward, grinning into warmer (if rather gray) weather now. . . be excellent to one another.

नमस्ते